key: cord-0885798-3p3rm52b authors: Pancrazzi, Alessandro; Magliocca, Pasqualino; Lorubbio, Maria; Vaggelli, Guendalina; Galano, Angelo; Mafucci, Manuela; Duranti, Diletta; Cortesi, Monica; Mazzeschi, Erica; Fabbroni, Sara; Viti, Gianluca; Tartaglia Polcini, Alessandro; Tripodo, Emanuela; Sanchini, Paola; Gervino, Silvana; Tacconi, Danilo; Dei, Simona; Mazzierli, Monica; D'Urso, Antonio; Ognibene, Agostino title: Comparison of serologic and molecular SARS-CoV 2 results in a large cohort in Southern Tuscany demonstrates a role for serologic testing to increase diagnostic sensitivity date: 2020-07-21 journal: Clin Biochem DOI: 10.1016/j.clinbiochem.2020.07.002 sha: 64e411dfbbca35480735c6974275cd4003a413dc doc_id: 885798 cord_uid: 3p3rm52b BACKGROUND: Since February 2019, Italian hospitals registered COVID-19 (COronaVIrus Disease 19) cases more often than the rest of the country. During this epidemic, health authorities requested swab tests, whileseeking new patient paths. METHODS: A dual laboratory approach was evaluated, consisting ofpatient care reports for viral RNA detection on swabs and rapid serological tests in 516 patients (192 symptomatic or paucisymptomatic and 324 asymptomatic). RESULTS: We found the molecular positive fraction equal to 12% (23/192) among symptomatic/paucisymptomatic (S/P) and 15.4% (50/324) in asymptomatic (As) sets. Among subsets, we observed serologically positive results, corresponding to 35% (8/23) for S/P and 38% (19/50) for As. Among molecular negative cases, we detected specific Immunoglobulin G or M (Ig G or Ig M) positivity in the S/P cohort equal to 6.6% (11/167) and 6% (15/246) in As cases. For indeterminate molecular results, we found S/P serological positivity equal to 100% (1/1) and 54% (13/24) in As patients. Wefound higher (p<0.05) seropositivity in older patients (n=8) among symptomatic and positives for viral RNA (n.23). CONCLUSIONS: It has been observed that a dual approach of serological and molecular tests detects a higher absolute number of disease cases in a pandemic context,whichcould improve monitoring and health surveillance efficacy. The age-related seropositivity frequency in this study, if confirmed, could enhance the validity of serological tests, especially in older patients.In these subjects, molecular positivity accompanied by serological positivity (distinct for M and G immunoglobulins) should help determine disease status and support decisions related to patient management. At the time of this writing in Tuscany, a central district of Italy, an outbreak of coronavirus disease 2019 (COVID -19) has been ongoing, caused by the 2019 novel coronavirus, and the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; previously called 2019-nCoV). Evidence suggests rapid local spread of the virus from Northwest regions (from Lombardy and Veneto). The first Italian patient was registered at the end of February and the Italian Civil Protection Department recorded the number of infected SARS-CoV-2 patients, consisting of 69,176. In Tuscany, there were 2,699 infected people. Given the experience of recent coronavirus contacts, we learned that the health care system must consider the risk of contagion between health workers and the spread of the virus within hospital environments. Numerous scientific publications [1] [2] [3] report studies on viral infection in hospital settings, which leads to the epidemiological problem; this is due to lower response effectiveness of the treatments for infected and non-infected patients. This problem could be resolved through hospital structure organization efficiency and valid diagnostic approaches for the suspicious infectious cases. The Tuscany District (TD), following the Coronavirus Regional Task Force (issuedFebruary 24, 2020) provisions [4], planned diagnostic-therapeutic strategies for the SARS COV2 pandemic [5] ,consisting of nasopharyngeal swab execution for all individuals with medium and high-risk contacts. In Italian areas, it is difficult to carry out swab tests forthewhole population, with the number of certified and authorized laboratories for research of viral RNA; above all, there is the procurement difficulty for the necessary resources to assist in the analytical process (reagents, instruments, and Personal Protective Equipment, PPE). As such, itis critical to secure more immediate and faster diagnostic strategies. In the Republic of China, the first nation afflicted with Covid-19, other diagnostic tools based on the qualitative determination of IgG and IgM antibodies against SARS COV2,were used. Qualitative antibody determinations have been performed with rapid response devices and applied in hospital triage for symptomatic patients [6] . The Italian Ministry of Health has not yet recommended Ig G and Ig M antibody detection for the diagnostic routine with COVID-19. In this study, the San Donato Hospital in Arezzo, in the Southeast Tuscany Local Health Unit (USL Toscana Sud-Est), evaluated the effectiveness of the combined use of antibody tests and molecular investigation for medium and high-risk contacts in asymptomatic, paucisymptomatic,orsymptomatic patients. This validated approach could help with diagnosis, for increased clinical safety management as well as to optimize the infrastructural resources for eligible patients, who must be placed in dedicated hospital sectors. This procedure, toscreensuspiciousinfectious cases, aims to reduce intrahospital spread of COVID-19 and to properly treat all patients. There is a great amount of evidence-based data in the literature, demonstratingthe detection value of immunoglobulin, which can identify cycles of the infectious virology sector [7] [8] [9] . This study proposes to link serological information to molecular data and to resolve diagnosis difficulties in a global emergency scenario. From March 17 to 21, 2020, we analyzed 516 nasopharyngeal swabs from patients in the Emergency Room (ER) and from subjects undergoing health surveillance by territorial and hospital prevention departments. All patients provided informed consentin accordance with the Declaration of Helsinki. At the triage phase, every patient has a clinical evaluation and isclassifiedas symptomatic/paucisymptomatic in all or one basal symptom (fever, cough,shortness of breath). The analyzedpopulationwas classified by age, gender, and symptomatology, in Table 1 This kit also contains an exogenous reaction control (IC), added during the first step in the pre-extraction phase, to determine the use of 10ng in each individual sample for analysis. This allows us to verify the correct conditions for reverse transcription and subsequent PCR. The analytical positivity determination system uses thisapproach:sampleswith valid amplification of all three targets, or only two, are considered positive. Samples without any fluorescence, detectable for three specific viral signals and valid amplification (within the 40th cycle) for IC Ct, are considered negative. The ones that do not present a fluorescence signal for viral targets and IC are defined as invalid, or as indeterminate in the case of single amplification of one viral target, with a valid IC signal.Automation Platform was used for sample processing: the Nimbus Platform (Hamilton, Italy),which islocally distributed from Arrow Diagnostics (San Marino and Vatican City, Italy). While collecting a swab collection, a blood sample is taken (purple cap tube, Ethylenediaminetetraacetic acid -EDTAadditive) to detect Immunoglobulins G and M (IgG and IgM) with a fast-determining kit (Acro Biotech, Inc.,Rancho Cucamonga, CA, USA). This Rapid Test consists of a membrane-based qualitative immunoassay for detection of IgG and IgM antibodies to the 2019-nCoV in whole blood, serum, or plasma. The kit has two components, IgG and IgM. Human IgG and IgM are recognized by the chromatographic method for anti-human IgG and IgM antibodies. A goat anti-mouse IgG is used for the control line system. As stated, results without a valid signal are considered invalid.All statistical analyses are assessed by GraphPad Instat by Graph Pad Software, v. 3.05,while applying One-way ANOVA, repeated measures ANOVA, the Kruskal-Wallis test, the Friedman test, and a comparison posttest Bonferroni. The molecular test, the gold standard to detect infection, along with basis data in Table 2 , can calculate the analytical limit value for serological testing: specificity (0.94), sensitivity (0.37), positive predictive value (PPV) (0.51), and negative predictive value (NPV) (0.94). INVALID 5 0 0 0 0 0/5 (0%) Gender distribution in ananalyzed cohort had 235 males and 281 females; among 55 SARS COV2 positives, there were 39 males (53%) and 34 females (47%), whilenegative cases were comprised of 229 females (55%) and 184 males (45%). Indeterminate cases had15 females (60%) and 10 males (40%). The gender-based incidence study does not reveal statistically significant differences (p=0.5), Table S1 and Graph S1 in Supplementary. The analyzed cohort has 324 asymptomatic and 192 symptomatic or paucisymptomatic patients (S/P). These two sets are stratified based on molecular and immunological results (Table 3) . Positivity incidence for patient age shows no statistical difference among cohorts of S/P and As ( Table S3 , Supplementary). In Italy, there are state directives from the Ministry of Health, which do not impose immunological screening fortheCOVID-19 emergency [11]. However, there is global interest from the scientific community on a combined approach for detecting infected patients and evaluating their clinical state [12, 13] . This study aimed to evaluate the multiple approach, based on molecular analysis of swabs and serological screening for Ig G and M, in order to decrease improper diagnosis and viral spread in the general territory and the hospital structures. The serological results distribution among molecularly screened patients ( . Only an analysis with reference standards and frequent patient monitoring allows the healthcare system to diagnose the actual state of the disease [15] [16] [17] . The incidence of Ig positive in a MOL POS cohort (27/73, 37%) indicates that the molecular method is the gold standard to screen patients, but revealsthat a consistent fraction are probably in the serologically undetectable set (onset of disease), or that Ig kits must be developed for a major specificity [18] . The problem of indeterminate cases regarding molecular response is becoming critical: in the screening phase, it raises doubts aboutspecificity of the kits used, as the monitoring context is an insidious aspect oftheinterpretation of infectious patients in clinical remission. The cross reactivity of the oligonucleotide's sequences in molecular kits [10] and the viral fluctuationknownto make up these pathologies [19] , represent a fundamental problem for patient monitoring. The systematic use of serological assessment could be a valid method of framing the patient's clinical status, in cases in which the molecular response is notexhaustive, or in which it provides a doubtful result. In this study, more than 50% (14/25, 56%) of the MOL IND cases were characterized by a positive response to immunoglobulins (Table 2 ). This data allows us to increase the clinical utility of the laboratory data. We found 1.9% (8/413) of Ig G positivity in MOL NEG ( Table 2 ). The incidence of only IgG positivity in the population has been an important parameter for evaluating herd immunity. This type of investigation, as mass controls increase, provides useful information for the trend of global immunity, and allows us to do a systematic check of disease relapse in immunized people [20] ,as well as toevaluate viral spread. Althoughcoronavirus literature reports possible advantages for the female sex [21] , the current 2019-nCoV (novel coronavirus) does not seem to show significant frequency in one sex compared to the other; however, in other aspects, there are statistically distinctive data for lethality [22] . The latter aspect has not been analyzed here, despite that this study confirms infection incidence as being comparable between males and females (Table S1 Supplementary). Analyzing the two S/P and As sets (Table 3) , it was observed that there were no statistically significant differences between exclusive molecular investigation and that for immunoglobulins (p>0.05). This confirms howseeking viral RNA in the swab sample is considered the gold standard for a diagnosis, but the total number of positive cases (POS MOL + SER) is higher thanthatidentified by analysis of molecular status alone (POS MOL). This isnotedin a viral spreading scenario to detect the greatest number of potentially infectious people (Graph 2). The cumulative positivity of molecular and serological tests must be considered in population screening to reduce false positives and to increase diagnostic strength. Serological positivity incidence in the MOL NEG and the MOL IND indicate that a combination of dual methodological approacheswould provide an efficient instrument for laboratory investigations -while at the same time, the data show low predictivity for single use serological tests (Graph 3). The dual analysis (molecular and serological) should be considered as a prudent approach to reduce false negatives. In this period, we performed a number of swabs, with various mass control managed by local health administrations, while mass screening is debated in its ability to solve the actual crisis [23, 24] . The need to increase oropharyngeal swabs and the consequent need to rapidly train staff, lacking practical experience,emphasizesanunsuitable sample. This aspect is particularly problematic, considering that the most widespread molecular analysis kits do not allow verification of the integrity of the collected material, so there is a concrete possibility of providing false negatives [25] . In our findings, the serological testcould be important to confirm negative and to clarify indeterminate molecular results,so health systems will have to consider the role of serology in their evaluation algorithms.. In other hand, considering large part of serological negative results among molecular positive cases, it'sundoubtedly necessary to conduct further research into serology approach. Novel antibodies, more specific than used, and use of CLIA (Chemiluminescent immunoassay) kits should be tested to raise predictivity value. In this study the molecular test has been confirmed gold standard method to define and to evaluate the disease status and the potential single patient infection power. The immunopositivity for older patients among MOL POS of the S/P set emerged in this study (Graph 1), as this data must be understood. First, a possible confounding effect linked to this case study must be considered. In a pandemic scenario, older patients (over 75 ) areconsidered the population most at risk for lethality, related to SARS-CoV-2 infection. Given this logic, it is also possible that there is distrust in visiting the hospital, which is a potentially risky environment. This approach was carried out by patients themselves, family members, home assistants,while family doctors may have selected a group of patients who should have turned to health facilities in an advanced disease state;thismay have been determined by immunopositivity data as being higher in older subjects. If we exclude this confounding effect, the biological interpretation of the data is complex and needs more studies, but wesuggest some hypotheses: early literature data report that binding and neutralizing antibodies are higher in older adults [26] ; these patients might have been exposed to coronavirus contacts for a longer time than younger ones. While examining the Gorse et al. study (2020) , this condition reveals a more frequent and specific immunoglobulin presence in older patients "due to the stimulation of antibodies against conserved cross-reactive antigens expressed by the current infecting strain of HCoV and, due to recall of immune memory, to other strains that previously infected the person earlier in life." If corroborated by other studies, this data could enhance the validity of serological tests in older patients. Molecular and serological analyses help the virologistto determine disease status andto support clinical decisions. The use of more accurate and sensitive serological systems, derived from recent studies on isotypes [27]would allow us to perform a more efficient dual approach for the patient's diagnosis, prognosis, and management. These data confirm that serological and molecular approaches should not be considered as two alternative systems for the monitoring of virusspreading, rather they seem to be two necessary applications. The molecular test allows to identify the most part of infected patients and the simultaneous serological investigation helps to clarify diagnostic response of the indeterminate molecular cases.This fact confirms that dual approach of molecular and serological tests must be recommended for a complete screening of population in pandemic scenario. Moreover, considering improving specificity of serological test in the future, it is probable that it will be confirmed a high incidence of coronavirus seropositivity in older people among symptomatic/paucisympthomatic patients. This data could clarify epidemiology of the COVIDand it could be useful to define correct diagnostic approach especially in emergency situation. Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission Middle East respiratory syndrome coronavirus transmission among health care workers: Implication for infection control Middle East respiratory syndrome coronavirus in the last two years: Health care workers still at risk Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis Interpretation of the presence of IgM and IgG antibodies in a rapid test for dengue: Analysis of dengue antibody prevalence in Fortaleza City in the 20th year of the epidemic Developments in the HCV Screening Technologies Based on the Detection of Antigens and Antibodies Laboratory diagnosis of emerging human coronavirus infections: state of the art Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR Laboratory Diagnosis of COVID-19 Infection: Current Issues and Challenges Updating the diagnostic criteria of COVID-19 "suspected case" and "confirmed case" isnecessary SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients Viral load of SARS-CoV-2 in clinical samples Viral Load Kinetics of SARS-CoV-2 Infection in the First Two Patients in Korea Developing antibody tests for SARS-CoV-2 COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses Recurrence of positive SARS-CoV-2 RNA in COVID-19: A case report Sex-Based Differences in Susceptibility to Severe Acute Respiratory Syndrome Coronavirus Infection Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study Covid-19 mass testing facilities could end the epidemic rapidly Drive-Through Screening Center for COVID-19: A Safe and Efficient Screening System against Massive Community Outbreak Potential False Negatives in the Molecular Diagnostics of COVID-19 Infection: Experience of an Italian Laboratory during the COVID-19 Epidemic Antibodies to coronaviruses are higher in older adults compared with younger adults, and binding antibodies are more sensitive than neutralizing antibodies in identifying coronavirus: Associated illnesses